2 References 1. Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapidacting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med. 2015; 66: 509–523 doi: 10.1146/annurev-med-053013-062946. 2. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet. 2016; 55: 1059–1077 doi: 10.1007/s40262-016-0383-6. 3. Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth. 1981; 63: 805–810 doi: 10.1093/bja/53.8.805. 4. Simons P, Olofsen E, Velzen M van, Lemmen M van, Dasselaar T van, Mohr P, Hammes F, Schrier R van der, Niesters M, Dahan A. S-Ketamine oral thin film-Part 2: Population pharmacodynamics of S-ketamine, S-norketamine and S-hydroxynorketamine. Front Pain Res (Lausanne). 2022; 3: 946487 doi: 10.3389/fpain.2022.946487. 5. Kamp J, Velzen M van, Olofsen E, Boon M, Dahan A, Niesters M. Pharmacokinetic and pharmacodynamic considerations for NMDA-receptor antagonist ketamine in the treatment of chronic neuropathic pain: an update of the most recent literature. Exp Opinion Drug Metab Toxicol. 2019; 15: 1033–1041 doi: 10.1080/17425255.2019.1689958. 6. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, al. et. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016; 533: 481–486 doi: 10.1038/nature17998. 7. Highland JN, Zanos P, Riggs LM, Georgiou P, Clark SM, Morris PJ, al. et. Hydroxynorketamine: pharmacology and potential therapeutic applications. Pharmacol Rev. 2021; 73: 763–791 doi: 10.1124/pharmrev.120.000149. 37
RkJQdWJsaXNoZXIy MTk4NDMw